Clinical Trial Search

Primary: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization…

Primary: Mean Concentration of Vancomycin in Subcutaneous Fat — 94.1; 3.2; 88.3; 5.0 µg/g — p=<0.0001

Primary: Part 1: Percentage of Participants With Adverse Events (AEs) — 95.5; 100.0 percentage of participants

Primary: Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm] — 70.6; 81.9…

Primary: Change in Waist Circumference — -2.3; -6.0; -4.0 cm — p=0.398

Primary: Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies — 100.0; 99.5; 98.7; 97.3 percentage of…

Primary: Percentage of Subjects With Hypercalcemia — 15.3 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions — 343; 207 participants

Primary: Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death — 125; 87 participants

Primary: Number of Participants With Serious Adverse Events (SAEs) — 1 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12) — 100 percentage of participants

Primary: Change From Baseline in Weekly Average Pain Score on the Visual Analog Scale at Week 10 — -1.33; -1.54 units on a scale

Primary: Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h) — 10.554; 15.824; 40.165; 52.291 units on a scale — p=<0.0001

Primary: Percentage of Participants With Disease Free Survival at 5 Years — 75.5; 83.2; 81.0 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.3; 93.9 percentage of participants — p=0.018